Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -39.61% is 94% above its 5-year average of -701.40%, near the high end of its 5-year range (-2092.14%–-23.19%).
89.92% above its 12-month average of -393.03%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -576.84%.
NET PROFIT MARGIN
-39.61%
NET PROFIT MARGIN AVG TTM
-393.03%
NET PROFIT MARGIN AVG 3Y
-545.93%
NET PROFIT MARGIN AVG 5Y
-701.40%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+89.92%
CURRENT VS 3Y AVG
+92.74%
CURRENT VS 5Y AVG
+94.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-11217.14%
vs the sector median at left
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.05M
Net Profit Margin
-39.61%
TTM Avg
-393.03%
3Y Avg
-545.93%
5Y Avg
-701.40%
Market Cap
$13.86M
Net Profit Margin
-1303.40%
TTM Avg
-1281.42%
3Y Avg
-1220.10%
5Y Avg
-1266.64%
Market Cap
$13.75M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.46M
Net Profit Margin
-8716.77%
TTM Avg
-1649.40%
3Y Avg
-960.30%
5Y Avg
-749.49%
Market Cap
$14.73M
Net Profit Margin
-153.28%
TTM Avg
-93.42%
3Y Avg
-97.51%
5Y Avg
-105.13%
Market Cap
$13.30M
Net Profit Margin
-3972.87%
TTM Avg
-1209.50%
3Y Avg
-3598.61%
5Y Avg
-2399.08%
Market Cap
$13.20M
Net Profit Margin
-651.27%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$14.94M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2405.08%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.05M | -39.61% | -393.03% | -545.93% | -701.40% |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | -1303.40% | -1281.42% | -1220.10% | -1266.64% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | -8716.77% | -1649.40% | -960.30% | -749.49% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | -153.28% | -93.42% | -97.51% | -105.13% |
| IN8bio, Inc. (INAB)vs › | $13.33M | 0.00% | 0.00% | 0.00% | 0.00% |
| Optimi Health Corp. (OPTH)vs › | $13.30M | -3972.87% | -1209.50% | -3598.61% | -2399.08% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | -651.27% | 0.00% | 0.00% | 0.00% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | 0.00% | 0.00% | 0.00% | -2405.08% |
| Passage Bio, Inc. (PASG)vs › | $13.11M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-30.4%
Net Profit Margin
-39.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -576.84% |
| 2025-12-31 | -23.19% |
| 2025-06-30 | -579.07% |
| 2024-12-31 | -392.39% |
| 2024-06-30 | -365.43% |
| 2023-12-31 | -961.71% |
| 2023-06-30 | -922.88% |
| 2022-12-31 | -255.03% |
| 2022-06-30 | -92.16% |
| 2021-12-31 | -1454.62% |
| 2021-06-30 | -2092.14% |
